Trial reportJournal of the International Society of Sports Nutrition2025
How reliable is the labeling of a commercial phytosteroid product? A 12-week randomized double-blind training study.
Trial report in Journal of the International Society of Sports Nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPhytosteroids like 20-hydroxyecdysone (20E) and diosgenin (DSG) have shown promising anabolic and performance-enhancing effects in in vitro, animal, and human studies. Combining phytosteroids is common in supplements, with early in vitro research suggesting additive effects via distinct signaling pathways. However, human studies on the combined effects of 20E and DSG are lacking. This study aimed to evaluate the anabolic and performance-enhancing potential of a commercially available 20E and DSG supplement.
methodsTwenty-eight resistance-trained young men were recruited for this study. Participants were randomized into two groups: a 20E and DSG (EcDi) group, and a placebo (Plac) group. Both groups performed free-weight resistance training three times per week for 12 weeks. The EcDi group received a commercially available phytosteroid product three times a day (as recommended on the label), while the Plac group received a placebo product. Assessments were conducted at four time points (T0, T1 [4 weeks], T2 [8 weeks], T3 [12 weeks]) and included measurements of one-repetition maximum (1-RM) for the squat (SQ) and bench press (BP) exercises, as well as body weight (BW), fat-free mass (FFM), muscle mass (MM), fat mass (FM), and muscle thickness of the pectoralis major (PM) and the proximal, middle and distal regions of the anterior (i.e.
resultsTwenty-four participants completed the study successfully. Significant improvements in 1-RM SQ and BP were observed across both groups, indicating a time but no specific group effect. Similarly, significant time effects without group effects were found for FFM, MM, FM and muscle thickness (anterior quadriceps femoris at 30%, lateral quadriceps femoris at 50% and PM). Subsequent analyses of the supplement revealed that less than 1% of the claimed 20E concentration and 10.4% of the claimed DSG concentration were present in the capsules. In addition, no biological activity or hypertrophic effects were detected in the C2C12 cells.
conclusionThis study demonstrated that the prescribed resistance training protocol resulted in significant anabolic and performance-enhancing effects that did not differ between groups. The lack of group-specific differences suggests that the tested phytosteroid supplement did not provide additional benefits. The significant discrepancy between the claimed and actual 20E and DSG concentration resulted in the lack of biological activity in C2C12 cells and likely contributed to the absence of measurable group-specific effects. To enhance the reliability of future phytosteroid research, we strongly recommend: (1) verification of active compound concentrations in supplements, its actual content and absence of potential contamination with prohibited substances, (2) confirmation of their biological activity using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.